A Phase I Study of the Hightly Selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer, NonSmall Cell Lung Cancer, and Other Advanced Solid Tumors (BLU-667-1101) (18164)

A Phase I Study of the Hightly Selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer, NonSmall Cell Lung Cancer, and Other Advanced Solid Tumors (BLU-667-1101) (18164)

Trial Category:
Other Solid Tumor
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Cancer Specialists, Omaha, NE

This is a phase I study evaluating the anti-tumor effect of a new drug in thyroid, lung, and other solid tumors. Please contact us for more information.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members